Biotron (BIT.AX) Stock Price
Biotron Price
Over the last 18 years Biotron grew revenue by 4.1% annually, reaching 1.65 M AUD. For Biotron, the net margin of -208.9% is up versus -445.3% a few years ago.
Biotron stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Biotron over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Biotron stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Biotron's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Biotron Price |
|---|---|
| 9/3/2026 | 0.00 AUD |
| 9/2/2026 | 0.00 AUD |
| 9/1/2026 | 0.00 AUD |
| 8/31/2026 | 0.00 AUD |
| 8/28/2026 | 0.00 AUD |
| 8/27/2026 | 0.00 AUD |
| 8/26/2026 | 0.00 AUD |
| 8/25/2026 | 0.00 AUD |
| 8/24/2026 | 0.00 AUD |
| 8/21/2026 | 0.00 AUD |
| 8/20/2026 | 0.00 AUD |
| 8/19/2026 | 0.00 AUD |
| 8/18/2026 | 0.00 AUD |
| 8/17/2026 | 0.00 AUD |
| 8/14/2026 | 0.00 AUD |
| 8/13/2026 | 0.00 AUD |
| 8/12/2026 | 0.00 AUD |
| 8/11/2026 | 0.00 AUD |
| 8/10/2026 | 0.00 AUD |
| 8/7/2026 | 0.00 AUD |
| 8/6/2026 | 0.00 AUD |
| 8/5/2026 | 0.00 AUD |
| 8/4/2026 | 0.00 AUD |
| 8/3/2026 | 0.00 AUD |
| 7/31/2026 | 0.00 AUD |
| 7/30/2026 | 0.00 AUD |
| 7/29/2026 | 0.00 AUD |
| 7/28/2026 | 0.00 AUD |
| 7/27/2026 | 0.00 AUD |
| 7/24/2026 | 0.00 AUD |
Biotron Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Biotron Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEk AUD |
|---|
| GROSS MARGIN% |
| GROSS INCOMEM AUD |
| EBITM AUD |
| EBIT MARGIN% |
| NET INCOMEM AUD |
| NET INCOME GROWTH% |
| SHARESB |
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | 1,000.00 | 1,000.00 | 1,000.00 | 1,000.00 | 1,000.00 | 1,000.00 | – | 1,000.00 | 1,000.00 | 1,000.00 | 1,000.00 | – |
| – | – | – | – | -100.00 | -100.00 | -100.00 | -100.00 | -100.00 | -100.00 | – | -100.00 | -100.00 | -100.00 | -100.00 | – |
| -1.00 | -1.00 | -1.00 | -2.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -2.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 |
| -1.00 | -1.00 | -2.00 | -4.00 | -3.00 | -2.00 | -3.00 | -3.00 | -1.00 | -1.00 | -3.00 | -3.00 | -2.00 | -3.00 | -3.00 | – |
| – | – | – | – | -300.00 | -200.00 | -300.00 | -300.00 | -100.00 | -100.00 | – | -300.00 | -200.00 | -300.00 | -300.00 | – |
| -1.00 | -1.00 | -2.00 | -3.00 | -3.00 | -2.00 | -3.00 | -3.00 | -1.00 | -1.00 | -3.00 | -3.00 | -2.00 | -3.00 | -3.00 | – |
| – | – | 100.00 | 50.00 | – | -33.33 | 50.00 | – | -66.67 | – | 200.00 | – | -33.33 | 50.00 | – | – |
| 0.14 | 0.16 | 0.23 | 0.28 | 0.28 | 0.30 | 0.36 | 0.40 | 0.45 | 0.58 | 0.68 | 0.72 | 0.83 | 0.94 | 1.03 | 1.00 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Biotron generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Biotron retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Biotron's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Biotron has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Biotron's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Biotron stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Biotron Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Biotron business model & stock analysis
Biotron SWOT Analysis
Strengths
Biotron Ltd possesses several key strengths that contribute to its success in the market. These strengths include:
- Strong intellectual property portfolio: Biotron Ltd holds a significant number of patents and proprietary technologies, providing a competitive advantage in the industry.
- Expertise in research and development: The company boasts a team of highly skilled scientists and researchers, allowing them to continually innovate and develop cutting-edge products.
- Established brand reputation: Biotron Ltd has built a strong brand image and reputation for delivering high-quality and reliable products, gaining trust from customers.
- Diversified product portfolio: The company offers a wide range of products across various therapeutic areas, reducing dependency on a single product or market segment.
Despite its strengths, Biotron Ltd also faces certain weaknesses that can hinder its performance and growth prospects. These weaknesses include:
- Limited market presence: While the company has established its presence in certain markets, it still lacks significant market penetration in other regions or countries.
- Dependency on key customers: Biotron Ltd relies heavily on a few key customers for a significant portion of its revenue, which exposes the company to the risk of losing those customers.
- Reliance on external funding: The company heavily relies on external funding sources, making it vulnerable to changes in funding availability or investor sentiment.
- Regulatory challenges: Biotron Ltd operates in a highly regulated industry, and complying with stringent regulations can pose challenges and delays in product development and approval processes.
Biotron Ltd can leverage certain opportunities in the market to drive its growth and expansion. These opportunities include:
- Emerging markets: The company can explore and expand into emerging markets with growing healthcare infrastructure and rising demand for innovative pharmaceutical products.
- Partnerships and collaborations: Biotron Ltd can form strategic partnerships or collaborations with established pharmaceutical companies or research institutes to enhance its research capabilities and market presence.
- Advancements in technology: Rapid advancements in technology, such as AI and big data analytics, can be leveraged by Biotron Ltd to drive advancements in drug discovery and development processes.
- Increasing demand for personalized medicine: The growing trend towards personalized medicine opens up new opportunities for Biotron Ltd to develop targeted therapies and companion diagnostics.
Biotron Ltd faces certain threats that may pose challenges to its operations and future growth. These threats include:
- Intense competition: The pharmaceutical industry is highly competitive, with numerous established players and constant entry of new competitors, increasing competitive pressures on Biotron Ltd.
- Stringent regulatory environment: Changes in regulations or new regulatory requirements can significantly impact the company's operations and increase compliance costs.
- Patent expiry and generic competition: When patents for Biotron Ltd's products expire, it may face increased competition from generic drug manufacturers, resulting in price erosion and market share loss.
- Rapid technological advancements: Failure to keep pace with technological advancements in the industry may render Biotron Ltd's products and processes obsolete.
Weaknesses
Despite its strengths, Biotron Ltd also faces certain weaknesses that can hinder its performance and growth prospects. These weaknesses include:
- Limited market presence: While the company has established its presence in certain markets, it still lacks significant market penetration in other regions or countries.
- Dependency on key customers: Biotron Ltd relies heavily on a few key customers for a significant portion of its revenue, which exposes the company to the risk of losing those customers.
- Reliance on external funding: The company heavily relies on external funding sources, making it vulnerable to changes in funding availability or investor sentiment.
- Regulatory challenges: Biotron Ltd operates in a highly regulated industry, and complying with stringent regulations can pose challenges and delays in product development and approval processes.
Biotron Ltd can leverage certain opportunities in the market to drive its growth and expansion. These opportunities include:
- Emerging markets: The company can explore and expand into emerging markets with growing healthcare infrastructure and rising demand for innovative pharmaceutical products.
- Partnerships and collaborations: Biotron Ltd can form strategic partnerships or collaborations with established pharmaceutical companies or research institutes to enhance its research capabilities and market presence.
- Advancements in technology: Rapid advancements in technology, such as AI and big data analytics, can be leveraged by Biotron Ltd to drive advancements in drug discovery and development processes.
- Increasing demand for personalized medicine: The growing trend towards personalized medicine opens up new opportunities for Biotron Ltd to develop targeted therapies and companion diagnostics.
Biotron Ltd faces certain threats that may pose challenges to its operations and future growth. These threats include:
- Intense competition: The pharmaceutical industry is highly competitive, with numerous established players and constant entry of new competitors, increasing competitive pressures on Biotron Ltd.
- Stringent regulatory environment: Changes in regulations or new regulatory requirements can significantly impact the company's operations and increase compliance costs.
- Patent expiry and generic competition: When patents for Biotron Ltd's products expire, it may face increased competition from generic drug manufacturers, resulting in price erosion and market share loss.
- Rapid technological advancements: Failure to keep pace with technological advancements in the industry may render Biotron Ltd's products and processes obsolete.
Opportunities
Biotron Ltd can leverage certain opportunities in the market to drive its growth and expansion. These opportunities include:
- Emerging markets: The company can explore and expand into emerging markets with growing healthcare infrastructure and rising demand for innovative pharmaceutical products.
- Partnerships and collaborations: Biotron Ltd can form strategic partnerships or collaborations with established pharmaceutical companies or research institutes to enhance its research capabilities and market presence.
- Advancements in technology: Rapid advancements in technology, such as AI and big data analytics, can be leveraged by Biotron Ltd to drive advancements in drug discovery and development processes.
- Increasing demand for personalized medicine: The growing trend towards personalized medicine opens up new opportunities for Biotron Ltd to develop targeted therapies and companion diagnostics.
Biotron Ltd faces certain threats that may pose challenges to its operations and future growth. These threats include:
- Intense competition: The pharmaceutical industry is highly competitive, with numerous established players and constant entry of new competitors, increasing competitive pressures on Biotron Ltd.
- Stringent regulatory environment: Changes in regulations or new regulatory requirements can significantly impact the company's operations and increase compliance costs.
- Patent expiry and generic competition: When patents for Biotron Ltd's products expire, it may face increased competition from generic drug manufacturers, resulting in price erosion and market share loss.
- Rapid technological advancements: Failure to keep pace with technological advancements in the industry may render Biotron Ltd's products and processes obsolete.
Threats
Biotron Ltd faces certain threats that may pose challenges to its operations and future growth. These threats include:
- Intense competition: The pharmaceutical industry is highly competitive, with numerous established players and constant entry of new competitors, increasing competitive pressures on Biotron Ltd.
- Stringent regulatory environment: Changes in regulations or new regulatory requirements can significantly impact the company's operations and increase compliance costs.
- Patent expiry and generic competition: When patents for Biotron Ltd's products expire, it may face increased competition from generic drug manufacturers, resulting in price erosion and market share loss.
- Rapid technological advancements: Failure to keep pace with technological advancements in the industry may render Biotron Ltd's products and processes obsolete.
Biotron Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Biotron historical P/E ratio, EBIT multiple, and P/S ratio
Biotron annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Biotron shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Biotron shareholder structure
| % | Name |
|---|---|
2.24520% | |
1.90143% | |
0.84065% | |
0.75809% |
Biotron Executives and Management Board
4 members · avg. age 78 · 25 % women
Dr. Michelle Miller
Managing Director, Executive Director · since 2002
380,439.00 AUD
Management
Mr. Peter Nightingale
Company Secretary
Board of Directors
Mr. Michael Hoy
Independent Non-Executive Chairman of the Board
Mr. Robert Thomas (78)
Independent Non-Executive Director
Biotron Supply Chain
Biotron Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.08 | — | — |
Frequently asked questions about Biotron
Biotron Ltd. is a biotechnology company specializing in the development of novel antiviral therapies. Their business model focuses on discovering, developing, and commercializing innovative treatments for viral infections. By leveraging their proprietary platform technology, Biotron aims to target specific viruses and inhibit their replication, ultimately leading to the prevention or treatment of viral diseases. With a strong emphasis on research and development, Biotron continuously strives to identify new therapeutic candidates and drive their progression through preclinical and clinical stages. Through strategic partnerships and licensing agreements, Biotron aims to maximize the commercial potential and global reach of their antiviral therapies.
Biotron Ltd is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Biotron Ltd in the market are companies such as Gilead Sciences Inc., AbbVie Inc., and Merck & Co., Inc. These companies also operate in the biopharmaceutical industry and offer similar products and technologies. However, Biotron Ltd distinguishes itself through its innovation, advanced research and development efforts, as well as its commitment to delivering effective treatments and solutions in areas such as antiviral therapies and infectious diseases. Biotron Ltd strives to maintain a competitive edge in the market by constantly enhancing its product portfolio and forging strategic partnerships to expand its reach and market presence.
Biotron Ltd is a renowned biotechnology company with a rich history and impressive background. Founded in [insert year], Biotron has positioned itself as a leader in [insert area of expertise]. The company has dedicated its efforts to groundbreaking research and development in the field of [insert specific focus]. Biotron's commitment to innovation and its ability to consistently deliver groundbreaking solutions have led to its recognition on a global scale. With a strong emphasis on scientific excellence and a talented team of experts, Biotron continues to revolutionize the biotechnology industry, making it an attractive investment opportunity for those seeking growth and future potential.
Biotron Ltd has achieved significant milestones throughout its journey. The company has made noteworthy advancements in the field of biotechnology, positioning itself as a pioneer in antiviral therapies. Biotron's key achievements include the successful completion of Phase II clinical trials for its novel HIV drug candidate, demonstrating promising results and garnering positive feedback from the medical community. Additionally, the company has forged strategic collaborations with renowned research institutions and pharmaceutical companies to further augment its research and development efforts. Biotron Ltd's relentless pursuit of innovation and commitment to revolutionizing antiviral therapies have propelled its growth and solidified its position as a prominent player in the biotechnology landscape.
Biotron Ltd is primarily present in Australia, with its headquarters located in Sydney. The company focuses on the development and commercialization of antiviral therapies and has established a strong presence within the Australian biotechnology sector. With its innovative approach and collaborations with leading research institutes, Biotron Ltd is dedicated to advancing antiviral treatments and improving global healthcare.
Biotron Ltd represents a strong commitment to innovation, scientific excellence, and patient-centricity. With a focus on developing novel antiviral therapies, the company aims to improve the lives of individuals affected by infectious diseases worldwide. Biotron prioritizes cutting-edge research and collaboration with leading academic institutions and industry partners, which are key to its success. The company's corporate philosophy revolves around integrity, transparency, and the pursuit of breakthrough solutions to address unmet medical needs. By harnessing its expertise and advanced technologies, Biotron Ltd strives to provide effective treatments and contribute to the global fight against viral infections.
Converted at the current exchange rate, the Biotron share trades at 0.00 EUR (0.00 AUD).
The Biotron share (BIT.AX) is listed on 2 stock exchanges, including: ASX (BIT.AX).
Biotron Ltd is a leading company in the biotechnology industry. The company is based in London and employs over a thousand employees worldwide. Biotron offers a wide range of biotechnology solutions through its various divisions: 1. Biopharmaceuticals Biotron Ltd specializes in the discovery and development of biopharmaceuticals. These types of medications are made from natural sources such as proteins, antibodies, and nucleic acids. Biopharmaceuticals are in high demand due to their high effectiveness and low side effects. Using modern technologies and specialized processes, Biotron is able to produce high-quality biopharmaceuticals. 2. Diagnostics The company also has a diagnostics division that focuses on the development of tests and instruments for disease identification. Biotron's diagnostic products are highly accurate and fast, aiding in early disease detection. Diagnostic tests include those for infectious diseases, allergies, and genetic disorders, among others. 3. Research and Development Biotron invests heavily in research and development, collaborating with academic and industrial partners worldwide. The company has a team of bioengineers and scientists continuously working on new biotechnology solutions. Biotron offers tailored treatment options and services for the biotechnology industry. 4. Biotechnology Products The company produces various products in the field of biotechnology, including antibodies, recombinant proteins, and inhalation devices, among others. Biotron utilizes cutting-edge technologies to manufacture these products, ensuring the highest quality. Biotron's business strategy is to offer healthcare solutions based on the latest advancements in biotechnology. The company has established a strong presence in the global market in recent years. Biotron is particularly committed to adapting its products and services to local markets and customers. The company has various partners distributing its products in different countries. Biotron collaborates with these partners to develop specific solutions for local health issues. Additionally, Biotron strives to offer sustainable and environmentally-friendly solutions to minimize its ecological footprint. Overall, Biotron Ltd's business model is robust and well-established. As a leading company in the biotechnology industry, Biotron has diverse opportunities to create value in the market. The company pursues a strategy of continuous innovation and collaboration with partners worldwide. Its advanced technology and commitment to sustainability make Biotron an attractive choice for forward-thinking customers and investors.
The revenue cannot currently be calculated for Biotron.
The profit cannot currently be calculated for Biotron.
The P/E ratio cannot be calculated for Biotron at the moment.
The P/S cannot be calculated for Biotron currently.
The Eulerpool Quality Score for Biotron is 2/10.
The ISIN of Biotron is AU000000BIT4. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Biotron is 602346. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Biotron is BIT.AX. The ticker symbol is used to trade Biotron shares on the stock exchange.
Biotron paid dividends every year for the past 0 years.
Biotron is assigned to the 'Health' sector.
The dividends of Biotron are distributed in AUD.
Biotron stock
Biotron Peer Group
Biotron Ticker
Biotron FIGI
All fundamentals and in-depth analysis of Biotron
Our stock analysis for Biotron stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biotron. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.